TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

Surgeons warn it is too early to recommend a TAVR-first strategy for low-risk patients

The Society of Thoracic Surgeons and European Association for Cardio-Thoracic Surgery say more information is still required before any conclusions can be made about the long-term benefits of TAVR in low-risk patients.

Kendra Grubb discusses TAVR vs SAVR and the most recent data to explain choices with patients.

TAVR or SAVR? Where things stand now, from a surgeon's perspective

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

Samir Kapadia, MD, Cleveland Clinic, explains the WATCH TAVR study results that combined LAAO with transcatheter aortic valve replacement at TCT 2023. #TCT2023 #TAVR #Watchman #LAAO

TAVR and LAAO at the same time? Samir Kapadia breaks down the WATCH-TAVR trial

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

TAVR patients with cancer face higher risks of hospital readmission, serious bleeding

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Video of Michael Reardon, MD, explaining details from the Evolute Low Risk 4-year results at TCT 2023.

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

Michael Reardon, MD, discussed his team's late-breaking results at TCT 2023 in San Francisco. 

TCT 2023 San Francisco

PARTNER 3, Evolut and more: TAVR takes the spotlight in 4 late-breaking clinical trials at TCT 2023

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

Akhil Narang, MD, director of the echocardiography laboratory at Northwestern Medicine explains the latest trends in structural heart interventional imaging. #ASE #ASE23 #ASE2023 #structuralheart #echofirst

The evolving roles of TEE and ICE in structural heart interventions

Akhil Narang, MD, explained that the two technologies can be used together to deliver high-quality patient care. 

A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

Displaying 129 - 136 of 417

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.